Overview

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

Status:
No longer available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The primary reason for this study is to further assess safety and efficacy data of the bortezomib/melphalan/prednisone (BMP) regimen in previously untreated and transplant ineligible multiple myeloma patients

Details

Lead Sponsor:

Janssen-Ortho Inc., Canada

Collaborator:

Ortho Biotech Canada

Treatments:

Bortezomib
Melphalan
Prednisone